After months of delay, Health Canada has released a final version of new regulations that are designed to cut prescription drug spending by the Canadian government, although the effort continued to draw harsh criticism from the pharmaceutical industry.
The changes will alter a decades-old framework that has been used by the agency’s Patented Medicine Prices Review Board to set prices. Notably, the PMPRB will no longer consider prices in the U.S. and Switzerland, which have some of the world’s highest for prescription medicines, when trying to set maximum prices that drug makers may charge in Canada.
About the Author Reprints
